Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Shandong Xinhua Pharmaceutical Co Ltd
Income from Continuing Operations
Shandong Xinhua Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
|
Income from Continuing Operations
¥506.1m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Income from Continuing Operations
¥6.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥3.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥4.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
See Also
What is Shandong Xinhua Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
506.1m
CNY
Based on the financial report for Dec 31, 2023, Shandong Xinhua Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 506.1m CNY.
What is Shandong Xinhua Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
13%
Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Shandong Xinhua Pharmaceutical Co Ltd have been 13% over the past three years , 13% over the past five years .